An observational study in Nodule Solitary Pulmonary and Non-small Cell Carcinoma, sponsored by Biodesix, Inc.. Active, not recruiting at 25 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-09-19.
Sponsored by Biodesix, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Solitary Pulmonary Nodule with a site in United States — 4 open to participants now, 8 under way, none of them phase 3. Solitary Pulmonary Nodule · United States.
Among the 27 studies in Solitary Pulmonary Nodule with a site in United States, this one is the 2nd largest by planned enrollment of the 15 observational ones that give a count, is one of 3 that started in 2020, is one of 15 observational ones, and was the 18th registered.
93 studies on the registry are indexed under Solitary Pulmonary Nodule; 20 are open to participants now.
Browse Solitary Pulmonary Nodule studies →4 of the 27 studies in Solitary Pulmonary Nodule with a site in United States are open now. Recruiting first, the newest first:
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 35–89
Veracyte, Inc. · Sites in United States, Puerto Rico
Ages 29–85
University of California, San Francisco · Sites in United States
Ages 40+
University of Florida · Sites in United States
Ages 50–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Solitary Pulmonary Nodule studies recruiting now, 6 (50%) set no upper age limit and 1 (8%) stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 40 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2
First in 2005; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 401 across 45 observational studies indexed under Solitary Pulmonary Nodule.
Median enrollment 37 across the 12 interventional studies, 187 across the 15 observational. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 27 have an industry lead sponsor. The 10 most frequent:
Biodesix, Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Biodesix, Inc. has 2 studies filed under Solitary Pulmonary Nodule — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 27 studies in Solitary Pulmonary Nodule with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates the how addition of the Nodify XL2 test result impacts the clinical management of newly identified solid lung nodules assessed as low to moderate risk of cancer.
A multicenter, randomized controlled study with a blinded control arm. Open label arm is observational for lung nodule management. The clinical trial will evaluate the clinical utility of the Nodify XL2 integrated classifier when used in the clinical management of newly identified solid lung nodules assessed as \< 50% risk of cancer by Mayo risk prediction algorithm.
Subjects with newly identified, solid lung nodule determined to be low-moderate risk of cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject's lung nodule of concern meets the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nodify XL2 results will be reported to the investigator and available to the subject.
Nodify XL2 results will not be available to the investigative site or subject.
Lung Nodule Diagnosis
Malignant diagnosis through histology/pathology or benign diagnosis through histology/pathology, radiologic stability or radiologic confirmation of nodule resolution
Time frame: Up to 24 months
Started Dec 2020 (actual). Primary completion is estimated for Dec 2025, 60 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Biodesix, Inc.